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Abstract
Background: Pancreatic cancer (PC) is one of the most aggressive and challenging cancer types to effectively treat,
ranking as the fourth-leading cause of cancer death in the United States. We investigated if exposures to angiotensin
II receptor blockers (ARBs) or angiotensin I converting enzyme (ACE) inhibitors after PC diagnosis are associated with
survival.
Methods: PC patients were identified by ICD-9 diagnosis and procedure codes among the 3.7 million adults living in
the Emilia-Romagna Region from their administrative health care database containing patient data on demographics,
hospital discharges, all-cause mortality, and outpatient pharmacy prescriptions. Cox modeling estimated covariateadjusted mortality hazard ratios for time-dependent ARB and ACE inhibitor exposures after PC diagnosis.
Results: 8,158 incident PC patients were identified between 2003 and 2011, among whom 20% had pancreas resection surgery, 36% were diagnosed with metastatic disease, and 7,027 (86%) died by December 2012. Compared to
otherwise similar patients, those exposed to ARBs after PC diagnosis experienced 20% lower mortality risk (HR=0.80;
95% CI: 0.72, 0.89). Those exposed to ACE inhibitors during the first three years of survival after PC diagnosis experienced 13% lower mortality risk (HR=0.87; 95% CI: 0.80, 0.94) which attenuated after surviving three years (HR=1.14;
95% CI: 0.90, 1.45).
Conclusions: The results of this large population study suggest that exposures to ARBs and ACE inhibitors after PC
diagnosis are significantly associated with improved survival. ARBs and ACE inhibitors could be important considerations for treating PC patients, particularly those with the worst prognosis and most limited treatment options.
Considering that these common FDA approved drugs are inexpensive to payers and present minimal increased risk
of adverse events to patients, there is an urgent need for randomized clinical trials, large simple randomized trials,
or pragmatic clinical trials to formally and broadly evaluate the effects of ARBs and ACE inhibitors on survival in PC
patients.
Keywords: Angiotensin I converting enzyme (ACE) inhibitors, Angiotensin receptor blockers (ARBs), Mortality,
Pancreatic cancer, Pharmacoepidemiology, Survival
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Background
Pancreatic cancer (PC) is among the most aggressive forms of cancer with an estimated incidence of
60,430 and causing 48,220 deaths in 2021, ranking it
as the fourth-leading cause of cancer death in the
United States [1]. Currently, surgical resection remains
the only treatment option consistently achieving
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significantly prolonged survival [2], but due to the
characteristically late presentation of the disease, only
10 – 20% of patients are candidates for resection [3].
Despite the significant research devoted to PC and its
treatment in those with unresectable disease, there
have been only modest improvements in overall survival relative to other common malignancies over the
last two decades [3].
Extensive preclinical data support the potential use
of angiotensin II receptor blockers (ARBs) and angiotensin I converting enzyme (ACE) inhibitors, two
common classes of medications FDA approved for
the management of hypertension [4], as antineoplastic agents in PC. In particular, ARBs have been shown
to exert multiple effects on PC cell metabolism and
cell cycle machinery [4–7]. An early retrospective
cohort study first introduced the potential association
between angiotensin inhibition and lower cancer incidence [8]. Subsequent studies used a variety of study
designs and failed to establish a link between these
agents and reduced cancer incidence [9, 10]. Following
more recent positive preclinical data, multiple studies
have also explored the association between angiotensin inhibition and overall survival in different types
of cancer. For example, both ARBs and ACE inhibitors were shown to be associated with an increase in
median overall survival in patients with non-squamous
cell lung cancer and patients with gastric cancer [11,
12]. Similar survival benefits from angiotensin inhibition also appear in PC. One small single-center retrospective study found that ARB or ACE inhibitor use
was associated with an increase in median overall survival in patients with advanced PC receiving gemcitabine monotherapy (15.1 months vs. 8.9 months) [13].
Another found that, among patients who survived at
least 6 months, ARB prescriptions were associated
with 24% lower mortality in PC patients undergoing
surgery for pancreas resection [14]. Two small phase
II clinical trials have been initiated to investigate if
including an ARB (losartan) in the treatment of nonmetastatic PC patients might improve success in surgical tumor resection [15, 16]. Some recent findings
suggest a possible benefit among locally advanced
patients [15].
To our knowledge, there are no large populationbased studies evaluating the associations of exposures
to ARBs and ACE inhibitors with mortality outcomes
in a general population of PC patients. We retrospectively evaluated a large population-based cohort of
patients diagnosed with PC to investigate the relationships between overall mortality and exposures to ARBs
and ACE inhibitors after PC diagnosis.
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Methods
Setting and study data

Italy’s National Health Service provides universal health
care coverage to all citizens. The data for this study were
drawn from the longitudinal health care database of
the approximately 3.7 million adults in the population
served by the Regional Health Service System of EmiliaRomagna, a northern Italian region of approximately 4.5
million inhabitants, between January 1, 2002 and December 31, 2011 [17]. The database provided administrative
linkable de-identified patient information records on
demographics, hospital discharge data (utilizations characterized by ICD-9-CM diagnosis and procedure codes,
as well as admission and discharge dates), all-cause
mortality (mortality status and date of either death or
censoring for moving out of the region or censoring for
surviving to the end of follow-up) and outpatient pharmacy data on individual prescriptions (Anatomical Therapeutic Chemical codes identifying which drugs were
prescribed). This database has been used extensively for
pharmacoepidemiologic research [18–20].
Case status, metastasis, and resection identification

Cases were those having hospital discharge records with
ICD-9-CM diagnosis codes indicating a primary or secondary diagnosis for malignant neoplasm of the pancreas
(i.e., 157.X; see Supplemental Table S1 for details). Lymph
node involvement and metastases were indicated by secondary malignancies at other sites (i.e., 196.X, 197.X,
198.X, 199.X; see Supplemental Table S2 for details).
Pancreatic resection was indicated by presence of pancreatectomy ICD-9 procedure codes (i.e., 52.XX; see Supplemental Table S3 for details).
Drug exposures, chemotherapy, and radiotherapy

We tracked exposure to ARBs and ACE inhibitors, as well
as exposure to drug classes potentially impacting cancer progression or pertinent diseases, including aspirin,
alpha blockers, beta blockers, calcium channel blockers, diuretics, non-steroidal anti-inflammatory drugs
(NSAIDs), statins, metformin, and other diabetes medications. The outpatient pharmacy records available indicated only what drug was prescribed and the date it was
filled. We could not determine what quantity was dispensed or the prescription duration.
Since we were tracking exposure to many drugs and fitting computationally intensive models accounting for the
timing of exposures in relation to survival, the drug exposures were tracked by parsing each patient’s survival time
into quarter-year periods, going forward from the time of
PC diagnosis to the time of death or censoring, as well as
backward 1 year, while noting in each quarter what drug
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classes had been prescribed and filled in the prior quarter. After PC diagnosis, a patient was considered exposed
to a given drug class only after the first quarter in which
they filled at least one prescription for a drug in that
class. That is, exposure initiation was lagged to the beginning of the next quarter and once a patient had incurred
exposure to a given drug class following their PC diagnosis, they were considered exposed to that drug class
for the remainder of their survival follow-up. To avoid
immortal time bias [21], these drug exposure indicator
variables were constructed as time-dependent covariates
allowed to change from unexposed to exposed for any PC
patient. Time dependent covariates were similarly constructed for chemotherapy, radiotherapy, and pancreatic
resection treatment status.
Statistical analysis and mortality modeling

The distributions of sample characteristics were summarized by medians with the first and third quartiles if
continuous and by frequency counts and percentages if
categorical. In addition to time-dependent ARB and ACE
inhibitor exposure indicator variables, potential confounders summarized and used in modeling included
demographic variables (age, age squared, and sex), a
geography variable (indicating if a patient’s residence lies
in a plain, in the hills, or in the mountains, which serves
as a proxy measure of population density in the region),
calendar time at diagnosis (quantified as years from
1/1/2002), chemotherapy, radiotherapy, pancreatic resection, metastasis at diagnosis, limitations to functional
status as indicated by home health care or oxygen prescriptions in the year prior to diagnosis and/or discharge
to a nursing home, the Elixhauser comorbidity measure
[22] for administrative data which sums 30 comorbidity
indicators, some of the most prevalent Elixhauser comorbidity indicators in these patients, exposure indicators for
each of the other nine drug classes in the year prior to PC
diagnosis, and time-dependent exposure indicators for
those other nine drug classes after PC diagnosis. Mortality follow-up ended on December 31, 2012. The cause of
death was not available.
The counting process style of input was used to construct a Cox proportional hazards all-cause mortality
model of the time-dependent ARB and ACE inhibitor
drug exposure variables and other time-dependent or
time-fixed covariates. We have used this methodology to
address a similar question on metformin exposure and
survival in patients with head and neck cancers [20] Supplemental Table S4 illustrates the counting process data
structure of two hypothetical PC patients showing their
diagnosis dates, last follow-up date, quarterly start/stop
follow-up time intervals, vital status, quarter index (looking back 5 quarters prior to PC diagnosis and forward
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until end of follow-up for prescriptions), ARB and ACE
inhibitor prescription indicators in each quarter, and
lagged time-dependent ARB and ACE exposure variables.
Models were also fitted to evaluate the mortality hazard
associated with exposures to ARBs or to ACE inhibitors
in subgroups of metastatic patients, pancreas resection patients, non-metastatic and non-resected patients,
patients with and without, respectively, ACE inhibitor
or ARB exposures in the year prior to PC diagnosis, and
patients having at least one comorbidity at PC diagnosis.
We detected a departure from the proportional hazards
assumption for ACE inhibitors, but not for ARBs (see
Supplemental Figure S1). This was addressed in each
Cox model by using time-dependent coefficients for ACE
inhibitor exposure, allowing its hazard ratio to change
during survivorship, while the ARB coefficient was constant over time.
All statistical data analyses were conducted by Scott W.
Keith, Ph.D. with SAS version 9.4 (SAS Institute, Cary,
NC, USA).

Results
We identified 8,158 PC patients diagnosed between January 2003 and December 2011 and followed them for allcause mortality through December 2012 (Table 1). Their
median age was 74.4 years and approximately half were
female (51.1%). Over a third of the patients had metastatic disease at diagnosis and 20% underwent surgery
for pancreatic resection. Though 19.3% of the patients
had diabetes mellitus coded at diagnosis, comorbidities
were not particularly common in this population as more
than 75% of the sample had no more than one comorbid condition recorded and more than half had none. In
the year prior to diagnosis, 18.0% of the patients were
exposed to ARBs, 31.5% to ACE inhibitors, and 53.7% to
neither. Over a median follow-up of 6.2 months, a total
of 7,027 (86.1%) patients died, with a median survival of
6.4 months (95% CI: 6.1, 6.6). At some point following PC
diagnosis, 18.0% and 31.8% were exposed to ARBs and
ACE inhibitors, respectively, each for a median of 2 quarters (Supplemental Table S5).
Time‑dependent ARB and ACE inhibitor exposure
indicators predicting reduced mortality

Preliminary assessment of the proportional hazards
assumption revealed that the association between mortality hazard and ARBs exposure after PC diagnosis was
reasonably constant during survival (Supplemental Figure S1A). However, mortality hazard associated with
ACE inhibitors after PC diagnosis changed after approximately 3 years of survival (Supplemental Figure S1B).
Based on a Cox model adjusted for potential confounders (Supplemental Table S6), in comparison to otherwise
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Table 1 Pancreatic cancer patient characteristics (N = 8,158)
Characteristic
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No.

%

Demographics
  Age at PC diagnosis, years
  Median [1st, 3rd quartiles]

74.4 [66.3, 81.5]

  Sex (female)

4,172

51.1

  Hill

2,290

28.1

  Mountain

444

5.4

  Plain

5,424

66.5

  2003-2005

2,455

30.1

  2006-2008

2,730

33.5

  2009-2011

2,973

36.4

  Metastatic

2,955

36.2

  Pancreas resection

1,613

19.8

  Chemotherapy

3,290

40.3

  Radiotherapy

855

10.5

  Geography

  Year of PC diagnosis

Pancreatic Cancer Related Variables

Comorbidities at PC diagnosis
  Elixhauser comorbidities count 22
  Median [1st, 3rd quartiles, max]

0 [0, 1, 7]

  At Least 1 Comorbidity

3,243

39.8

  Diabetes Mellitus

1,576

19.3

  Chronic Pulmonary Disease

499

6.1

  Congestive Heart Failure

316

3.9

  Liver Disease

262

3.2

  Deficiency Anemias

259

3.2

  Peripheral Vascular Disease

233

2.9

  Valvular Disease

188

2.3

  Neurological Disorders

181

2.2

  Hypothyroidism

164

2.0

  Pulmonary Circulation Disease

147

1.8

  Depression

129

1.6

  Chronic Blood Loss

114

1.4

  Home health care or O2 prescription in year prior to PC diagnosis

743

9.1

  Discharged to nursing home

576

7.1

  ACE inhibitors

2,571

31.5

  ARBs

1,467

18.0

  Alpha blockers

384

4.7

  Beta blockers

1,695

20.8

  Calcium channel blockers

1,740

21.3

  Diuretics

1,676

20.5

  Aspirin

2,122

26.0

  NSAIDs

209

2.6

  Statins

1,417

17.4

  Metformin

992

12.2

  Other diabetes medications

1,110

13.6

  Most Prevalent Elixhauser Comorbidities

Functional Status at PC diagnosis

PC patients with Drug Rx exposures in year prior to PC diagnosis
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Table 1 (continued)
Characteristic

No.

%

  Non-users of ACEs and ARBs

4,377

53.7

  Other Antihypertensive Rx

1,440

17.7

  No Other Antihypertensive Rx

2,937

36.0

  None of the above medications

2,318

28.4

Time from PC diagnosis to end of follow-up, months
  Median [1st, 3rd quartiles]
All-cause mortality

6.2 [2.4, 16.0]
7,027

86.1

Abbreviations: angiotensin I converting enzyme (ACE); angiotensin II receptor blocker (ARB); hypertension prescriptions (HTN Rx); pancreatic cancer (PC); prescription
(Rx)

similar patients, those exposed to ARBs after their PC
diagnosis experienced 20% lower mortality hazard (Fig. 1;
HR = 0.80; 95% CI: 0.72, 0.89) and those exposed to ACE
inhibitors during the first three years of survival after PC
diagnosis experienced 13% lower mortality hazard (Fig. 2;
HR = 0.87; 95% CI: 0.80, 0.94).
However, unlike for ARBs, the reduced mortality risk
associated with ACE inhibitors was no longer evident
after three years of survival (Fig. 2; HR = 1.14; 95% CI:
0.90, 1.45).
Subgroup analyses

The mortality hazards associated with ARBs and ACE
inhibitors after diagnosis in particular subgroups of PC
patients are also shown in Figs. 1 and 2, respectively.
These results stem from independent Cox models – one
fitted for each subgroup including those with metastatic
disease at diagnosis, pancreas resection, no metastases
at diagnosis and no pancreas resection, those with and
those without ARB or ACE inhibitor exposure in the year
prior to diagnosis, and those with at least one comorbidity. Significant survival benefits were associated with

exposure to ARBs after PC diagnosis in each subgroup,
except among the subset of non-metastatic non-pancreas
resection patients. Exposure to ARBs after PC diagnosis
was associated with a 28% reduction in mortality risk
among resected patients (HR = 0.72; 95% CI: 0.55, 0.96),
a 24% reduction in mortality risk among PC patients
with metastatic disease (HR = 0.76; 95% CI: 0.64, 0.90),
and a 26% reduction in mortality risk among PC patients
with at least one comorbidity (HR = 0.74; 95% CI: 0.64,
0.87). The mortality hazard benefit associated with exposure to ACE inhibitors during the first three years of
survival after PC diagnosis appears to be largely driven
by the subgroups of patients with no metastatic disease
at diagnosis and not resected (HR = 0.83; 95% CI: 0.74,
0.93) and/or those with no ARB or ACE inhibitor exposures in the year prior to their PC diagnosis (HR = 0.78;
95% CI: 0.67, 0.89). When the subgroup having no ARB
or ACE inhibitor exposures in the year prior to PC diagnosis were further restricted to those with no comorbid
hypertension diagnosis or other antihypertensive medication exposures that year, the associations were stronger
for ARBs after PC diagnosis (Supplemental Table S7: HR

Fig. 1 Mortality hazard ratios and 95% confidence intervals for ARB exposure after pancreatic cancer diagnosis
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Fig. 2 Mortality hazard ratios and 95% confidence intervals for ACE inhibitor exposure after pancreatic cancer diagnosis. This risk relationship
depends on how long the patient has lived after diagnosis

= 0.65; 95% CI: 0.47, 0.91) and for ACE inhibitors during the first 3 years of survival after PC diagnosis (Supplemental Table S8: HR = 0.72; 95% CI: 0.59, 0.89). There
were no subgroups that showed survival benefits from
exposure to ACE inhibitors after three years of survival.
Supplemental Table S9 shows the crude and adjusted
HRs for both ARBs and ACE inhibitor exposures in all
patients and in each subgroup. The differences observed
between the respective crude and adjusted HRs suggest
that confounding was strong for some estimates, such as
for the ARB HR among metastatic patients: crude HR =
1.08 vs. adjusted HR = 0.76.

Discussion
Having analyzed over 8,158 PC case records, this is by
far the largest study of PC patient survival related to
post-diagnosis exposure to ARBs or ACE inhibitors. Our
results suggest that these drugs are significantly associated with improved prognosis. The PC patients that
received at least one ARB prescription after their PC
diagnosis experienced substantial mortality risk reductions of 20% in general, but 28% among the resected PC
patients, 24% among those with metastatic PC at diagnosis, and 26% among those with at least one comorbidity.
ACE inhibitors were associated with improving survival

in PC patients, but only during their first three years of
survival in which they experienced mortality risk reductions of 13% in general and 17% among non-metastatic
patients not resected – a subgroup likely representing
locally advanced PC patients that, in our study, did not
appear to benefit as much as others from ARB exposure.
A plausible explanation for the attenuation of this association after 3 years of survival is confounding by indication. Once these PC patients had survived the cancer
at least that long and were in remission, other causes of
death had become more common and patients treated
with ACE inhibitors likely experienced greater risk of
death from non-PC causes due to their diabetes, hypertension, or other indications.
Similar to our study, at least two clinical studies and
several other observational studies of renin-angiotensin
system (RAS) inhibitors have shown survival benefits
in PC patients independently of chemotherapy [23], in
patients undergoing gemcitabine treatment [13, 24], and
in patients undergoing surgical resection for PC [14]. A
recent single-arm phase II clinical trial was initiated to
investigate losartan’s potential for improving success in
surgical tumor resection among locally advanced pancreatic ductal adenocarcinoma (PDA) patients receiving FOLFIRINOX followed by chemoradiotherapy [15].
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Their findings suggest a possible benefit from losartan
and also support further clinical studies, such as the
currently ongoing 4-arm randomized phase II clinical
trial of the effects of losartan and/or immunotherapy
(nivolumab) in combination with FOLFIRINOX and stereotactic body radiotherapy (SBRT) on improving success in surgical tumor resection in patients with localized
PC (NCT03563248) [16]. However, our study is the first
to analyze survival following ARB and ACE inhibitors
exposure in a general PC population with focused subgroup analysis of metastatic PC patients showing significantly improved survival in that particularly high-risk
subpopulation of patients.
To understand how ARBs and ACE inhibitors may have
affected improved survival in PC patients, consider that
angiotensin II is a central hormone in the RAS that helps
maintain fluid and electrolyte homeostasis throughout
the body [4]. Past evidence shows that angiotensin II
and the RAS are also expressed at the local tissue level
and have been associated with influencing tissue angiogenesis, cellular proliferation, and apoptosis through
paracrine functions [25]. Angiotensin II has two welldefined receptors that are prevalent in human tissue, the
angiotensin II type 1 (AT1) and the angiotensin II type 2
(AT2) receptors. The AT1 receptor is primarily responsible for the cardiovascular and renal benefits seen with
angiotensin inhibition, but is also a potential target for
antineoplastic agents. In particular, specific inducement
of the AT1 receptor is linked with increased cancer cell
proliferation, growth, and reduced rates of apoptosis [26].
The AT2 receptor, however, is only expressed in adult
tissue in a limited capacity and is suspected to antagonize many proposed antineoplastic functions of the AT1
receptor [27]. ARBs and ACE inhibitors primarily regulate the RAS through either the competitive inhibition
of angiotensin-converting-enzyme responsible for producing angiotensin II or directly inhibiting the binding
of angiotensin II at the A
 T1 receptor. Therefore, as ACE
inhibitors prevent the systemic formation of angiotensin II, they inhibit the effect of angiotensin II on both the
AT1 and AT2 receptors while ARBs, as competitive receptor antagonists, only inhibit angiotensin II at its primary
binding site, the A
 T1 receptor. Initial studies identified
angiotensin II as a strong mediator of VEGF expression
in PDA cells due to an AT1 dependent pathway [6, 7].
Direct inhibition of the A
 T1 receptor with the ARB losartan was shown to reduce pancreatic tumor size in mice
and rats, presumably due to suppression of VEGF-mediated angiogenesis [28, 29]. Losartan also appears to have
a significant impact on PDA cell survival through stimulation of p53 directed apoptosis [30] and was shown to
improve intratumoral drug delivery to PC tumors in mice
[31]. In vitro studies also show that losartan, when used
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with nanoparticle doxorubicin, reduced tumor size and
increased intratumoral distribution of doxorubicin nanoparticles likely due to inhibition of collagen I production
within cells. [32]. As angiotensin II inhibition is reported
to decrease the expression of various growth factors
which influence the tumor–stromal interaction, exposure
to ARBs and ACE inhibitors may modulate the tumor
microenvironment against PC by decreasing the stromal volume and improving drug delivery to increase the
efficacy of chemotherapeutics. [33]. Theories behind the
antineoplastic potential of ACE inhibitors remain unsettled; multiple studies examining inhibition of the A
 T2
receptor have produced competing mechanisms. Stimulation of the A
 T2 receptor is associated with reducing
PC cell growth, a benefit that disappeared with use of an
AT2-specific antagonist [34]. However, at least one study
found that AT2 inhibition was associated with decreased
fatty acid synthase translation and decreased PC cell survival suggesting there may be alternate mechanisms for
ACE inhibitors in PC [35].
There are important limitations and strengths to our
claims-based retrospective cohort study. There were no
records available in the database on behavioral exposures, such as smoking history, that could be important
risk factors for PC and hypertension and would be useful as covariates in our models. The outpatient pharmacy
records did not indicate the dose of any of the drugs prescribed. As such, we were unable to describe the doseresponse relationship between post PC diagnosis ARB
or ACE inhibitor exposure and survival. Moreover, we
could not ascertain how well the patients adhered to their
prescriptions. We recognize the inherent limitations of
using an administrative healthcare database for research
purposes. For instance, diagnosis and procedures coding
in the database could have led to a misclassification of
metastasis at diagnosis or an incomplete identification of
exactly which patients had which comorbidities. We do
not think that the likelihood of being coded for comorbidity was imbalanced between those who were and
those who were not prescribed ACE inhibitors or ARBs
in such a way that would have biased the results on their
exposures and mortality away from the null (i.e., latent
comorbidity having higher prevalence among those
exposed to ACE/ARBs leading to stronger associations
between these exposures and mortality). It is important
to note, though, that we have been able to capture and
adjust our models for critically important information on
comorbid conditions through tracking outpatient drug
prescriptions and using them as baseline and time-varying exposure covariates. Despite covariate adjustments,
the comparison of ARB or ACE inhibitor exposed and
unexposed PC patients could have been confounded to
some degree by selection bias related to the severity or
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complications of their respective PC cases. Still, our careful utilization of the available covariate information and
construction of time-dependent drug exposure variables
and considerations for time-dependent risk parameter
coefficients supports the internal validity of the results.
Having comprehensive survival, outpatient prescribing,
and comorbidity data on all PC cases in the entire EmiliaRomagna adult population of Italy from 2003 to 2011 is
a great and perhaps unique strength of our study which
supports the generalizability of our findings.
What could be the clinical implications of the study
findings? The prospect of repurposed inexpensive and
well-tolerated medications, such as ARBs and ACE inhibitors, having an impact on survival in PC patients is certainly intriguing from a clinical standpoint – especially
considering that there are so few effective interventions
available for PC patients, besides surgical resection when
possible. Still, the associations we have estimated in this
observational study need to be interpreted with caution
as they are only a step in the process toward arriving at
reliable answers to questions on clinical utility. However,
it may be reasonable for PC patients requiring treatment
for other indications, such as hypertension, to preferentially use ARBs or ACE inhibitors over other antihypertensives, and for PC patients already using ARBs or ACE
inhibitors to weigh the potential for a survival benefit
when considering deprescribing preventative treatments
for chronic conditions. Given the relative strength and
consistency of survival benefit associated with ARBs in
our data, as compared with ACE inhibitors, it is tempting
to prioritizing ARBs, such as losartan, for interventional
studies in the general population of newly diagnosed PC
patients. However, we believe that further observational
studies and clinical trials of both classes are warranted.

Conclusions
More prospective clinical evidence is needed for determining the benefits of ARBs and ACE inhibitors on
survival in PC patients before considering treatment
recommendations on the use, duration, and dosing of
these drugs in the broad target population. Nevertheless,
our study suggests there is hope for prolonged survival
among PC patients who take ARBs or ACE inhibitors. We
have shown compelling associations between reduced
mortality risk and exposure to ARBs or ACE inhibitors,
including analysis of how long after PC diagnosis survival benefits might be expected. Considering that these
common FDA approved drugs are inexpensive to payers
and present minimal increased risk of adverse events to
patients, there is an urgent need for randomized clinical trials, large simple randomized trials, and pragmatic
clinical trials to formally and broadly evaluate the effects
of ARBs and ACE inhibitors on survival in PC patients.
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